queen of domesticity, found herself under the microscope over the summer and into the fall while being scrutinized by the Justice Department, the Securities and Exchange Commission, and a Congressional committee. The three were investigating whether she had inside information that prompted her to sell about 4,000 shares of ImClone stock. She made the trade the day before the FDA announced it had declined to review ImClone's new cancer drug—news that sent shares tumbling.